SG11201609739UA - Derivatives of dolaproine-dolaisoleuine peptides - Google Patents

Derivatives of dolaproine-dolaisoleuine peptides

Info

Publication number
SG11201609739UA
SG11201609739UA SG11201609739UA SG11201609739UA SG11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA SG 11201609739U A SG11201609739U A SG 11201609739UA
Authority
SG
Singapore
Prior art keywords
dolaisoleuine
dolaproine
peptides
derivatives
dolaisoleuine peptides
Prior art date
Application number
SG11201609739UA
Other languages
English (en)
Inventor
Brian Alan Mendelsohn
Julien Dugal-Terrier
Stuart Daniel Barnscher
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of SG11201609739UA publication Critical patent/SG11201609739UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201609739UA 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides SG11201609739UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004084P 2014-05-28 2014-05-28
PCT/US2015/032704 WO2015183978A1 (en) 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides

Publications (1)

Publication Number Publication Date
SG11201609739UA true SG11201609739UA (en) 2016-12-29

Family

ID=54699722

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609739UA SG11201609739UA (en) 2014-05-28 2015-05-27 Derivatives of dolaproine-dolaisoleuine peptides

Country Status (9)

Country Link
US (3) US20170190735A1 (enrdf_load_stackoverflow)
EP (1) EP3149024B9 (enrdf_load_stackoverflow)
JP (3) JP2017519740A (enrdf_load_stackoverflow)
KR (1) KR102413079B1 (enrdf_load_stackoverflow)
CN (1) CN107041139A (enrdf_load_stackoverflow)
ES (1) ES2883023T3 (enrdf_load_stackoverflow)
RU (1) RU2747989C2 (enrdf_load_stackoverflow)
SG (1) SG11201609739UA (enrdf_load_stackoverflow)
WO (1) WO2015183978A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2747989C2 (ru) * 2014-05-28 2021-05-18 Эдженсис, Инк. Производные пептидов долапроин-долаизолейина
US10722593B2 (en) * 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
EP4321522A1 (en) * 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024230625A1 (zh) * 2023-05-06 2024-11-14 荣昌生物制药(烟台)股份有限公司 一种奥瑞他汀衍生物中间体的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2172069T3 (es) * 1991-08-09 2002-09-16 Teikoku Hormone Mfg Co Ltd Derivado tetrapeptidico.
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (ja) * 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
ATE282630T1 (de) 1993-10-01 2004-12-15 Teikoku Hormone Mfg Co Ltd Dolastatin-derivate
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) * 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20030083263A1 (en) * 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ES2309233T3 (es) * 2001-09-20 2008-12-16 Aska Pharmaceutical Co., Ltd. Cristales de derivado tetrapeptidico.
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
AU2005259002B2 (en) * 2004-07-02 2011-01-27 Neutec Pharma Limited Treatment of cancer
US8288352B2 (en) * 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
ZA200711069B (en) * 2005-06-30 2009-03-25 Virobay Inc HCV inhibitors
WO2007008603A1 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
CA2713557C (en) 2008-01-30 2016-06-07 Pieris Ag Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
NO2842575T3 (enrdf_load_stackoverflow) * 2008-03-18 2018-02-24
CA2720699C (en) * 2008-04-11 2018-01-02 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers using antibodies that specifically bind to denatured cd70
EP3501546A3 (de) 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung
RU2566693C2 (ru) * 2011-07-08 2015-10-27 Сименс Акциенгезелльшафт Система слоев с двухслойным металлическим слоем
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
PL3327027T3 (pl) * 2011-11-17 2021-06-28 Pfizer Inc. Cytotoksyczne peptydy i ich koniugaty przeciwciało lek
ES2734259T3 (es) * 2012-05-15 2019-12-05 Concortis Biosystems Corp Conjugados de fármacos, métodos de conjugación y usos de los mismos
SG11201503431TA (en) * 2012-11-07 2015-05-28 Pfizer Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
RU2015116480A (ru) * 2012-11-07 2016-12-27 Пфайзер Инк. Анти-notch3 антитела и конъюганты антител с лекарственным средством
RU2747989C2 (ru) * 2014-05-28 2021-05-18 Эдженсис, Инк. Производные пептидов долапроин-долаизолейина

Also Published As

Publication number Publication date
JP7292366B2 (ja) 2023-06-16
CN107041139A (zh) 2017-08-11
EP3149024A4 (en) 2018-06-06
RU2747989C2 (ru) 2021-05-18
WO2015183978A1 (en) 2015-12-03
KR20170005495A (ko) 2017-01-13
US20200325170A1 (en) 2020-10-15
JP2022027896A (ja) 2022-02-14
EP3149024B1 (en) 2021-05-12
RU2016150426A (ru) 2018-07-03
JP2017519740A (ja) 2017-07-20
KR102413079B1 (ko) 2022-06-24
US11312748B2 (en) 2022-04-26
EP3149024B9 (en) 2021-10-27
RU2016150426A3 (enrdf_load_stackoverflow) 2018-12-20
EP3149024A1 (en) 2017-04-05
US20220204557A1 (en) 2022-06-30
JP6995160B2 (ja) 2022-01-14
JP2020128405A (ja) 2020-08-27
US20170190735A1 (en) 2017-07-06
ES2883023T3 (es) 2021-12-03

Similar Documents

Publication Publication Date Title
SG11201706729SA (en) Derivatives of sobetirome
SI3845221T1 (sl) Trdne oblike sofosbuvirja
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
GB201418562D0 (en) Peptides
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL246979A0 (en) Crystalline forms of sofosbuvir
PL3418273T3 (pl) Pochodne flawaglin
IL248773A0 (en) History of naphthyridinedione
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
GB201401877D0 (en) Peptides
RS59218B1 (sr) Novi derivati cyp-eikosanoida
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
IL249130B (en) Preparation of piperidine-4-carbothioamide
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201504211D0 (en) Use of peptides
GB201420645D0 (en) Peptides
GB201412731D0 (en) Peptides
GB201410686D0 (en) Peptides
GB201415235D0 (en) Trans-locating peptide
GB201409010D0 (en) Peptides
GB201405078D0 (en) Peptides
GB201404910D0 (en) Trans-locating peptide
GB201405952D0 (en) Proteins
GB201403914D0 (en) Proteins